Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Corporation stock logo
GKOS
Glaukos
$83.85
-3.6%
$88.03
$77.10
$163.71
$4.84B0.76915,196 shs101,469 shs
Envista Holdings Corporation stock logo
NVST
Envista
$19.34
-4.2%
$20.74
$14.22
$23.00
$3.22B1.012.43 million shs844,903 shs
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
$6.70
-7.2%
$6.49
$2.48
$22.42
$1.30BN/A108,571 shs68,535 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$109.06
-3.5%
$117.48
$55.00
$145.50
$3.75B2.081.26 million shs237,376 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Corporation stock logo
GKOS
Glaukos
-0.72%+2.80%-4.33%-16.16%-32.92%
Envista Holdings Corporation stock logo
NVST
Envista
-1.90%-1.97%-3.07%0.00%+11.42%
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
+7.44%+11.25%+6.96%+44.69%+721,999,900.00%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-4.30%-2.66%+4.34%+0.46%-17.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Corporation stock logo
GKOS
Glaukos
$83.85
-3.6%
$88.03
$77.10
$163.71
$4.84B0.76915,196 shs101,469 shs
Envista Holdings Corporation stock logo
NVST
Envista
$19.34
-4.2%
$20.74
$14.22
$23.00
$3.22B1.012.43 million shs844,903 shs
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
$6.70
-7.2%
$6.49
$2.48
$22.42
$1.30BN/A108,571 shs68,535 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$109.06
-3.5%
$117.48
$55.00
$145.50
$3.75B2.081.26 million shs237,376 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Corporation stock logo
GKOS
Glaukos
-0.72%+2.80%-4.33%-16.16%-32.92%
Envista Holdings Corporation stock logo
NVST
Envista
-1.90%-1.97%-3.07%0.00%+11.42%
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
+7.44%+11.25%+6.96%+44.69%+721,999,900.00%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-4.30%-2.66%+4.34%+0.46%-17.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Corporation stock logo
GKOS
Glaukos
2.69
Moderate Buy$118.0040.73% Upside
Envista Holdings Corporation stock logo
NVST
Envista
2.24
Hold$21.088.99% Upside
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
1.00
SellN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.50
Moderate Buy$125.4014.98% Upside

Current Analyst Ratings Breakdown

Latest SSII, GKOS, TMDX, and NVST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Envista Holdings Corporation stock logo
NVST
Envista
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
10/8/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Envista Holdings Corporation stock logo
NVST
Envista
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/7/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$140.00 ➝ $110.00
10/6/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
10/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$103.00
10/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$103.00
9/29/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
9/27/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M12.54N/AN/A$13.91 per share6.03
Envista Holdings Corporation stock logo
NVST
Envista
$2.55B1.26$1.56 per share12.39$17.05 per share1.13
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
$20.65M62.81N/AN/A$0.08 per share83.75
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$531.29M7.00$1.52 per share71.75$6.81 per share16.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$1.65N/AN/AN/A-21.43%-8.59%-6.61%10/29/2025 (Confirmed)
Envista Holdings Corporation stock logo
NVST
Envista
-$1.12B$0.3260.4615.981.102.11%4.84%2.68%10/30/2025 (Estimated)
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
-$19.15MN/A0.00N/A-40.20%-40.41%-20.80%N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.9357.0676.27N/A13.49%28.02%8.64%10/27/2025 (Estimated)

Latest SSII, GKOS, TMDX, and NVST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2025Q3 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.27N/AN/AN/A$639.49 millionN/A
10/29/2025Q3 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.27N/AN/AN/A$122.55 millionN/A
10/27/2025Q3 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.37N/AN/AN/A$145.33 millionN/A
7/31/2025Q2 2025
Envista Holdings Corporation stock logo
NVST
Envista
$0.24$0.26+$0.02$0.16$638.21 million$682.10 million
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26-$0.24+$0.02-$0.34$115.49 million$124.12 million
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48$0.92+$0.44$0.92$146.64 million$157.37 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Envista Holdings Corporation stock logo
NVST
Envista
N/AN/AN/AN/AN/A
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
5.51
4.69
Envista Holdings Corporation stock logo
NVST
Envista
0.46
2.44
2.08
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A
2.59
1.66
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.61
9.86
9.17

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Envista Holdings Corporation stock logo
NVST
Envista
N/A
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
Envista Holdings Corporation stock logo
NVST
Envista
0.66%
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.35 million54.02 millionOptionable
Envista Holdings Corporation stock logo
NVST
Envista
12,300166.18 million165.09 millionOptionable
SS Innovations International, Inc. stock logo
SSII
SS Innovations International
4193.59 millionN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.09 million31.70 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Glaukos stock logo

Glaukos NYSE:GKOS

$83.85 -3.17 (-3.64%)
As of 11:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Envista stock logo

Envista NYSE:NVST

$19.34 -0.85 (-4.20%)
As of 11:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

SS Innovations International stock logo

SS Innovations International NASDAQ:SSII

$6.70 -0.52 (-7.20%)
As of 11:10 AM Eastern

AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$108.80 -4.18 (-3.70%)
As of 11:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.